Lobectomy versus sublobar resection for stage I non-small cell lung cancer: an umbrella review of evidence quality, overlap, surgical-extent heterogeneity, and survival outcomes [0.03%]
肺叶切除术与亚肺叶切除术治疗Ⅰ期非小细胞肺癌的有效性、异质性和生存结果的伞式评价
Xiang Lin,Jingwen Zhang,Beinuo Wang et al.
Xiang Lin et al.
Background: Whether sublobectomy achieves survival outcomes comparable to lobectomy in Stage I non-small cell lung cancer (NSCLC) remains controversial. With increasing adoption of parenchymal-sparing surgery, a comprehen...
Laparoscopic transabdominal approach for radical excision of low-lying presacral cyst: a case report and narrative mini-review [0.03%]
经腹腔镜下低位骶前囊肿根治性切除的术式：1例报告及短篇综述
Xirang Wang,Maoxing Liu,Fei Tan et al.
Xirang Wang et al.
Background: Presacral cysts are clinically rare, deeply located, and pose diagnostic challenges prior to surgery. Complete surgical resection is the primary treatment. Laparoscopic techniques offer minimally invasive adva...
Baseline 18F-FDG PET/CT habitat radiomics versus dual-channel deep learning for predicting interim PET early metabolic response in diffuse large B-cell lymphoma: a comparative study [0.03%]
基底18F-FDG PET/CT生境影像组学与双通道深度学习预测弥漫性大B细胞淋巴瘤中期PET代谢反应的比较研究
Yu He,Shun Wang,Yingchun Li et al.
Yu He et al.
Purpose: To develop baseline ¹8F-FDG PET/CT habitat radiomics and dual-channel deep learning models for the prediction of early metabolic response (EMR) on interim PET (iPET) in patients with DLBCL and compare their perf...
Case Report: Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases [0.03%]
个例报告：EGFR突变型伴获得性ROS1融合和脑转移的NSCLC的动态TKI联合策略
Hua Yang,Yong Da,Ge Shen et al.
Hua Yang et al.
The development of a ROS1 fusion as a bypass signaling pathway mediating resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) is rare, with only sporadic cases reported in the literature. Consequently, no consensus exists o...
Lei Shen,Yechuan Xu,Jun Li et al.
Lei Shen et al.
Introduction: Splenic tumors are infrequently encountered in clinical practice, with a metastatic tumor incidence estimated to be approximately 2%-4% of all splenic tumors. Metastatic tumors originating from the liver are...
Haitao Wu,Youyuan Chen,Peng Sun et al.
Haitao Wu et al.
Objective: To investigate the clinical, imaging, pathological, and molecular characteristics of polymorphous low-grade neuroepithelial tumor of the young (PLNTY) and provide references for clinical diagnosis and treatment...
Evaluating the efficacy and safety of first-line immunotherapy for metastatic triple-negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials with a focus on PD-L1 expression [0.03%]
一线免疫治疗转移性三阴性乳腺癌的疗效和安全性评价：以PD-L1表达为重点的随机对照试验系统综述与网状Meta分析
Yanxiao Sun,Longtao Zhang,Dong Guo
Yanxiao Sun
Introduction: This study systematically reviewed randomized controlled trials (RCTs) and conducted a Bayesian network meta-analysis to evaluate first-line immunotherapy regimens for metastatic triple-negative breast cance...
Epidemiology, outcomes of treatment, and survival of cervical cancer in Kazakhstan: a nationwide population-based study [0.03%]
哈萨克斯坦宫颈癌流行病学、治疗效果及生存研究：一项基于全国人口的队列研究
Aidana Rakhmankulova,Yesbolat Sakko,Abduzhappar Gaipov et al.
Aidana Rakhmankulova et al.
Background: Cervical cancer remains one of the major medical and public health issues in Kazakhstan. In 2024, Kazakhstan launched a campaign to vaccinate 11- to 13-year-old girls, demonstrating successful implementation. ...
Lorenzo Cohen,Eran Ben-Arye
Lorenzo Cohen
Over the past several decades, cancer treatment has evolved from a discipline centered almost exclusively on tumor-directed modalities to one that increasingly acknowledges the complex interplay of biological, behavioral, psychosocial, spir...
Exercise in regional breast cancer with neoadjuvant anthracycline-based chemotherapy with immune checkpoint-inhibition: study protocol for a prospective randomised controlled trial [0.03%]
基于蒽环类化疗联合免疫检查点抑制的区域乳腺癌运动前瞻性随机对照试验研究方案
Elena Murr,Sabine Grill,Marion Kiechle et al.
Elena Murr et al.
Background: Anthracycline-based chemotherapy and immune checkpoint inhibition-increasingly used together in triple negative breast cancer (BC)-both cause cardiotoxicity and decline in peak oxygen consumption (VO2peak). Wh...